Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

Before the introduction of erythropoiesis-stimulating agents (ESAs) in 1989, repeated transfusions given to patients with end-stage renal disease caused iron overload, and the need for supplemental iron was rare. However, with the widespread introduction of ESAs, it was recognized that supplemental iron was necessary to optimize hemoglobin response and allow reduction of the ESA dose for economic reasons and recent concerns about ESA safety. Iron supplementation was also found to be more efficacious via intravenous compared to oral administration, and the use of intravenous iron has escalated in recent years. The safety of various iron compounds has been of theoretical concern due to their potential to induce iron overload, oxidative stress, hypersensitivity reactions, and a permissive environment for infectious processes. Therefore, an expert group was convened to assess the benefits and risks of parenteral iron, and to provide strategies for its optimal use while mitigating the risk for acute reactions and other adverse effects.


Authors: Iain C. Macdougall, Andreas J. Bircher, Kai-Uwe Eckardt, Gregorio T. Obrador, Carol A. Pollock, Peter Stenvinkel, Dorine W. Swinkels, Christoph Wanner, G?nter Weiss, Glenn M. Chertow


Reference: Kidney Int Volume 89, Issue 1, January 2016, Pages 28–39; doi:10.1016/j.kint.2015.10.002


Additional Info

  • Language:
  • Contains Audio:
  • Content Type:
  • Source:
  • Event:
    Other events
  • Year:
  • Members Only:

Read 240 times

Last modified on Monday, 08 February 2016 10:38

Scroll to Top